Cargando…

Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis

BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematic...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shijie, Tong, Xiang, Zhang, Tianli, Wang, Dongguang, Liu, Sitong, Wang, Lian, Fan, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801498/
https://www.ncbi.nlm.nih.gov/pubmed/35111830
http://dx.doi.org/10.3389/fcvm.2021.809594
_version_ 1784642474042458112
author Zhang, Shijie
Tong, Xiang
Zhang, Tianli
Wang, Dongguang
Liu, Sitong
Wang, Lian
Fan, Hong
author_facet Zhang, Shijie
Tong, Xiang
Zhang, Tianli
Wang, Dongguang
Liu, Sitong
Wang, Lian
Fan, Hong
author_sort Zhang, Shijie
collection PubMed
description BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematically searched for epidemiological studies reporting the prevalence of SAPH up to July 2021. Two reviewers independently performed the study selection, data extraction, and quality assessment. Studies were pooled using random-effects meta-analysis. RESULTS: This meta-analysis included 25 high-quality studies from 12 countries, with a pooled sample of 632,368 patients with sarcoidosis. The prevalence of SAPH by transthoracic echocardiography in Europe, the United States and Asia was 18.8% [95% confidence interval (CI): 11.1–26.5%], 13.9% (95% CI: 5.4–22.4%) and 16.2% (95% CI: 7.1–25.4%) separately, and the overall pooled prevalence was 16.4% (95%CI: 12.2–20.5%). By right heart catheterization (RHC), the pooled prevalence of SAPH was 6.4% (95% CI: 3.6–9.1%) in general sarcoidosis population, and subgroup analyses showed that the prevalence of SAPH was 6.7% (95% CI: 2.4–11.0%) in Europe and 8.6% (95% CI: −4.1 to 21.3%) in the United States. Further, the prevalence of pre-capillary PH was 6.5% (95% CI: 2.9–10.2%). For the population with advanced sarcoidosis, the pooled prevalence of SAPH and pre-capillary PH by RHC was as high as 62.3% (95% CI: 46.9–77.6%) and 55.9% (95% CI: 20.1–91.7%), respectively. Finally, the pooled prevalence of SAPH in large databases with documented diagnoses (6.1%, 95% CI: 2.6–9.5%) was similar to that of RHC. Substantial heterogeneity across studies was observed for all analyses (I(2) > 80%, P < 0.001). CONCLUSIONS: The sarcoidosis population has a relatively low burden of PH, mainly pre-capillary PH. However, as the disease progresses to advanced sarcoidosis, the prevalence of SAPH increases significantly.
format Online
Article
Text
id pubmed-8801498
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-88014982022-02-01 Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis Zhang, Shijie Tong, Xiang Zhang, Tianli Wang, Dongguang Liu, Sitong Wang, Lian Fan, Hong Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Sarcoidosis-associated pulmonary hypertension (SAPH) is associated with poor prognosis, conferring up to a 10-fold increase in mortality in patients with sarcoidosis, but the actual prevalence of SAPH is unknown. METHODS: The PubMed, Embase, and Cochrane Library databases were systematically searched for epidemiological studies reporting the prevalence of SAPH up to July 2021. Two reviewers independently performed the study selection, data extraction, and quality assessment. Studies were pooled using random-effects meta-analysis. RESULTS: This meta-analysis included 25 high-quality studies from 12 countries, with a pooled sample of 632,368 patients with sarcoidosis. The prevalence of SAPH by transthoracic echocardiography in Europe, the United States and Asia was 18.8% [95% confidence interval (CI): 11.1–26.5%], 13.9% (95% CI: 5.4–22.4%) and 16.2% (95% CI: 7.1–25.4%) separately, and the overall pooled prevalence was 16.4% (95%CI: 12.2–20.5%). By right heart catheterization (RHC), the pooled prevalence of SAPH was 6.4% (95% CI: 3.6–9.1%) in general sarcoidosis population, and subgroup analyses showed that the prevalence of SAPH was 6.7% (95% CI: 2.4–11.0%) in Europe and 8.6% (95% CI: −4.1 to 21.3%) in the United States. Further, the prevalence of pre-capillary PH was 6.5% (95% CI: 2.9–10.2%). For the population with advanced sarcoidosis, the pooled prevalence of SAPH and pre-capillary PH by RHC was as high as 62.3% (95% CI: 46.9–77.6%) and 55.9% (95% CI: 20.1–91.7%), respectively. Finally, the pooled prevalence of SAPH in large databases with documented diagnoses (6.1%, 95% CI: 2.6–9.5%) was similar to that of RHC. Substantial heterogeneity across studies was observed for all analyses (I(2) > 80%, P < 0.001). CONCLUSIONS: The sarcoidosis population has a relatively low burden of PH, mainly pre-capillary PH. However, as the disease progresses to advanced sarcoidosis, the prevalence of SAPH increases significantly. Frontiers Media S.A. 2022-01-17 /pmc/articles/PMC8801498/ /pubmed/35111830 http://dx.doi.org/10.3389/fcvm.2021.809594 Text en Copyright © 2022 Zhang, Tong, Zhang, Wang, Liu, Wang and Fan. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Zhang, Shijie
Tong, Xiang
Zhang, Tianli
Wang, Dongguang
Liu, Sitong
Wang, Lian
Fan, Hong
Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title_full Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title_fullStr Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title_full_unstemmed Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title_short Prevalence of Sarcoidosis-Associated Pulmonary Hypertension: A Systematic Review and Meta-Analysis
title_sort prevalence of sarcoidosis-associated pulmonary hypertension: a systematic review and meta-analysis
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801498/
https://www.ncbi.nlm.nih.gov/pubmed/35111830
http://dx.doi.org/10.3389/fcvm.2021.809594
work_keys_str_mv AT zhangshijie prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT tongxiang prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT zhangtianli prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT wangdongguang prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT liusitong prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT wanglian prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis
AT fanhong prevalenceofsarcoidosisassociatedpulmonaryhypertensionasystematicreviewandmetaanalysis